Published in Proc Natl Acad Sci U S A on October 02, 2006
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med (2015) 2.55
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res (2008) 2.29
Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate (2009) 1.18
Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem (2012) 1.13
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer (2009) 1.12
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate (2012) 1.11
A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem (2008) 1.11
Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? Neoplasia (2008) 1.05
Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate (2010) 1.01
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate (2010) 1.00
DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. Mol Endocrinol (2010) 0.99
Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. Oncogene (2010) 0.97
Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene (2012) 0.96
MCM7 interacts with androgen receptor. Am J Pathol (2008) 0.96
Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res (2008) 0.96
Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer (2009) 0.95
Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol (2007) 0.95
A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression. Nucleic Acids Res (2009) 0.95
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
RNA editing of androgen receptor gene transcripts in prostate cancer cells. J Biol Chem (2008) 0.93
Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. J Biol Chem (2012) 0.91
Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. J Cell Physiol (2011) 0.88
Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo. Prostate (2012) 0.87
Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts. Prostate (2009) 0.87
Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5α-reductase inhibitors. Am J Clin Exp Urol (2014) 0.86
Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis? PLoS One (2013) 0.82
Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. Prostate (2012) 0.82
Cell-cycle-dependent regulation of androgen receptor function. Endocr Relat Cancer (2015) 0.79
Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells. Int J Cancer (2011) 0.78
The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J (2016) 0.76
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes (2016) 0.76
PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity. Oncotarget (2016) 0.75
Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth. Evid Based Complement Alternat Med (2016) 0.75
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. Oncotarget (2015) 0.75
Rationale for Bipolar Androgen Therapy (BAT) for Metastatic Prostate Cancer. Cell Cycle (2017) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Regulation of chromosome replication. Annu Rev Biochem (2000) 3.68
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry (1998) 2.11
DNA replication and progression through S phase. Oncogene (2005) 1.99
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res (2005) 1.83
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol (2005) 1.67
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate (2003) 1.60
PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate (2006) 1.55
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther (2005) 1.53
Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res (2004) 1.50
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther (2003) 1.39
Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res (2005) 1.31
Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun (2000) 1.29
hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J (2003) 1.28
Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate (2001) 1.23
Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res (2005) 1.23
Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int (2005) 1.19
hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated transcription and interacts with SWI/SNF-like BAF complexes. Mol Endocrinol (2005) 1.11
Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol (2005) 1.03
The ubiquitin-specific protease USP10 modulates androgen receptor function. Mol Cell Endocrinol (2005) 1.03
Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. J Cell Physiol (2003) 1.00
Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. Prostate (2004) 0.99
In vivo dynamics and kinetics of pKi-67: transition from a mobile to an immobile form at the onset of anaphase. Exp Cell Res (2005) 0.89
"Decoy" of androgen-responsive element induces apoptosis in LNCaP cells. Prostate (1999) 0.85
Flow cytometric analysis of androgen receptor expression in human prostate tumors and benign tissues. Clin Cancer Res (2000) 0.83
Fixation-associated quantitative variations of DNA fluorescence observed in flow cytometric analysis of hemopoietic cells from adult diploid frogs. Cytometry (1990) 0.82
NaCl-aided Hoechst 33258 staining method for DNA quantification and its application. Histochemistry (1989) 0.80
Temperature-induced chromatin changes in ethanol-fixed cells. J Histochem Cytochem (1988) 0.80
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res (2008) 2.29
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia (2008) 2.07
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res (2006) 2.02
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol (2005) 1.78
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res (2006) 1.65
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate (2003) 1.60
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res (2006) 1.60
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev (2004) 1.60
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol (2011) 1.58
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58
LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol (2011) 1.58
In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem (2004) 1.57
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer (2009) 1.56
The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol Ther (2005) 1.56
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate (2007) 1.55
PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate (2006) 1.55
Practical methods for tissue microarray construction. Methods Mol Med (2005) 1.54
ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 1.54
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52